Gene Therapy Review: Gene and Cell Therapy Resource
TAP Biosystems Announce New Webinar Programme on Applications of Micro Bioreactors
- Written by Editorial Team
Specialists at Cobra Biologics and TAP Discuss Advances in Bioprocess Development
Cambridge, UK: TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications, today announced that it will be running the first of its new webinar programme on Thursday June 14th, offering free access to scientific presentations on its innovative micro scale bioreactor, ambr™.
Two Bioprocess experts, Ulrica Skoging-Nyberg, Delivery Team Leader, from Cobra Biologics and Dr Barney Zoro, Product Manager, from TAP Biosystems will be presenting data on the application of the ambr system and its potential in bioprocess development at two, live webinars on Thursday June 14th at 11am GMT and 5pm GMT. To join the webinars, scientists simply need to register at: www.tapbiosystems.com/ambr_webinar/ambrwebinar_invite.htm
During the webinars, Dr Zoro will be discussing the applications of the ambr system, in particular its effectiveness in CHO cell culture applications such as clone screening, process optimisation and design of experiments. He will also be presenting published field data using ambr, which validates ambr as a true scale-down model.
Skoging-Nyberg will explain how Cobra Biologics has implemented a disposable, automated and fully traceable workflow for their high throughput maxXpress cell line development platform. She will be discussing how ambr is being used to speed up Cobra’s process development by transferring clones from TAP’s Cello System to ambr and then into single use bioreactors.
Dr Barney Zoro, ambr Product Manager at TAP Biosystems stated: "We are delighted to be hosting a webinar with Cobra Biologics as it will allow ambr users and researchers evaluating micro-scale bioreactors to discover how their work could benefit from using this technology. We look forward to discussing how ambr can improve the efficiency of clone selection and scalable process development with scientists that join us for these informative webinars on June 14th.”
- Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency: chronic granulomatous disease.
- Sengenics to Launch Global Biomarker Discovery and Clinical Trials Service Based on Oxford Gene Technology's Patented Functional Protein Array
- Are There Limits to What Gene Therapy Can Achieve in Treating Retinal Blindness?
- RetroSense Therapeutics Announces Notice of Allowance for New U.S. Patent Application Broadly Covering Optogenetic Approaches to Vision Restoration
- Gene therapy to aid lung transplants